Pregnant Women. Eclampsia
Conditions
Interventions
After Administration of folic acid for all the Pregnant women at the dose of 5 mg For 36 week,
blood sampling from all the pregnant women Participations before Administration and after 36 weeks
Treatment - Drugs
After Administration of folic acid for all the Pregnant women at the dose of 5 mg For 36 week,
blood sampling from all the pregnant women Participations before Administration and after 36 weeks
Sponsors
Drug Applied Research Center
Eligibility
Sex/Gender
Female
Age
20 Years to 30 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Pregnant wemon with the average age of 20-30 years Exclusion criteria: Without history of heart disease; chronic hypertension; diabetes mellitus; renal disease; collagen tissue disease; history of preterm labor; abortion; drug taking calcium and ferrous sulfate; liver disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Homocysteine. Timepoint: before Administration and 36 weeks of gestation. Method of measurement: ELISA method using primary and secondary antibodies by ELISA reader.;Lipoprotein (a). Timepoint: before Administration and 36 weeks of gestation. Method of measurement: Nephlometric Method by Autoanalyzer. | — |
Secondary
| Measure | Time frame |
|---|---|
| LDH. Timepoint: before Administration and 36 weeks of gestation. Method of measurement: Autoanalyzer.;Urea. Timepoint: before Administration and 36 weeks of gestation. Method of measurement: Autoanalyzer.;Creatinine. Timepoint: before Administration and 36 weeks of gestation. Method of measurement: Autoanalyzer.;Platelet. Timepoint: before Administration and 36 weeks of gestation. Method of measurement: Cell counter.;Urinary creatinine. Timepoint: before Administration and 36 weeks of gestation. Method of measurement: Autoanalyzer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Nadereh Rashtchizadeh
Drug Applied Research Center
Outcome results
None listed